Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 01 - 04 save search
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
Published: 2021-01-04 (Crawled : 17:00) - biospace.com/
AMPE | $0.286 0.0% 8K
|
Health Technology
|
| O: 0.63%
H: 2.5%
C: -7.5%
covid trial treatment covid-19
HAWKINS ANNOUNCES IT HAS EXTENDED ITS WATER TREATMENT FOOTPRINT WITH ACQUISITIONS IN LOUISIANA
Published: 2021-01-04 (Crawled : 15:00) - globenewswire.com
HWKN 4 | $77.14 0.25% 0.25% 65K
|
Distribution Services
|
| O: 1.13%
H: 0.49%
C: -1.89%
acquisition acquisitions treatment
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.47%
H: 0.66%
C: -0.58%
cancer therapy treatment application nivolumab
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated TumorsHPN328, Harpoon’s fourth TriTAC® T cell engager, enters clinical development
Published: 2021-01-04 (Crawled : 15:00) - biospace.com/
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 Study
Published: 2021-01-04 (Crawled : 13:03) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 7.21%
H: 1.76%
C: -4.52%
treatment phase 2 phase 2/3
Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
Published: 2021-01-04 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 3.13%
H: 17.16%
C: 13.54%
lung cancer cancer t-cell treatment
Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis
Published: 2021-01-04 (Crawled : 12:03) - globenewswire.com
PASG | News | $1.27 3.25% 3.15% 39K
|
Health Technology
|
| O: 2.35%
H: 11.2%
C: 7.45%
gene therapy fda clearance fda therapy treatment gene therapies application clearance
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
Published: 2021-01-04 (Crawled : 11:03) - globenewswire.com
INZY | $4.4 0.0% 480K
|
Health Technology
|
| O: 4.26%
H: 11.85%
C: 8.6%
trial phase 3 phase 1 phase 2 treatment authorized
Tiziana Life Sciences plc announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Published: 2021-01-04 (Crawled : 10:00) - biospace.com/
TLSA | News | $0.781 0.77% 0.77% 330K
|
Health Technology
|
| O: 18.81%
H: 9.58%
C: 7.5%
covid life science brazil trial antibody foralumab
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Published: 2021-01-04 (Crawled : 07:01) - globenewswire.com
TLSA | News | $0.781 0.77% 0.77% 330K
|
Health Technology
|
| O: 18.81%
H: 9.58%
C: 7.5%
covid life science brazil trial antibody foralumab
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.